| 0.021 0.001 (5%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.02 | 1-year : | 0.03 |
| Resists | First : | 0.02 | Second : | 0.02 |
| Pivot price | 0.02  |
|||
| Supports | First : | 0.01 | Second : | 0.01 |
| MAs | MA(5) : | 0.02 |
MA(20) : | 0.02 |
| MA(100) : | 0.02 |
MA(250) : | 0.02 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 14.9  |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 0.05 | Low : | 0.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRTX ] has closed above bottom band by 4.9%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0.02 - 0.02 | 0.02 - 0.02 |
| Close: | 0.02 - 0.02 | 0.02 - 0.02 |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Thu, 13 Nov 2025
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Thu, 30 Oct 2025
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MyChesCo
Wed, 22 Oct 2025
Galera (OTC: GRTX) to sell dismutase mimetics to Biossil; $3.5M upfront, up to $105M - Stock Titan
Wed, 22 Oct 2025
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Wed, 22 Oct 2025
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Tue, 21 Oct 2025
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 36.2 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 2,120 (K) |
| Shares Short P.Month | 2,660 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.05 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|